



#1100
dli
2/24/03
RECEIVED
FEB 24 2003
TECH CENTER 1600/1292
Attorney Docket No. 218654
DHHS Ref. No. E-087-96/2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Chamberlain et al.

Application No. 09/838,987

Filed: April 20, 2001

For: HETEROLOGOUS
BOOSTING IMMUNIZATION

Art Unit: 1632

Examiner: Wilson, M.

PRELIMINARY AMENDMENT AND REMARKS

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Please enter the following amendments and consider the following remarks.

AMENDMENTS

IN THE SPECIFICATION:

Replace the paragraph beginning at page 1, line 3, with the following:

NK
This application is a continuation of U.S. patent application no. 09/171,086, filed January 22, 1999, now abandoned, which is the national phase of international patent application no. PCT/US97/06632, filed April 21, 1997, now lapsed, which claims the benefit of U.S. provisional patent application no. 60/015,893, filed April 22, 1996, now lapsed.

Replace the paragraph beginning at page 5, line 7, with the following:

25/26
101
Fig. 1: Compares the effect of repetitive immunization of the recombinant vaccine vectors on tumor growth and long-term survival in BALB/c mice intravenously challenged with 10^5 CT26.CL25 tumor cells to establish pulmonary metastases. The mice were primed with various vectors 3 days post-intravenous challenge and then boosted with same amount and array of vectors 17 days after tumor inoculation. **Fig. 1A** – data of mice primed with no immunogen (None) and later boosted by either no